PMID- 17706550
OWN - NLM
STAT- MEDLINE
DCOM- 20071030
LR  - 20070820
IS  - 1359-6446 (Print)
IS  - 1359-6446 (Linking)
VI  - 12
IP  - 15-16
DP  - 2007 Aug
TI  - Immunogenicity of protein therapeutics and the interplay between tolerance and 
      antibody responses.
PG  - 674-81
AB  - Patients can mount sustained immune responses to protein therapeutics with the 
      production of neutralizing antibodies (NAbs) that can compromise efficacy or 
      safety of these drugs. Dendritic cells (DCs) are required for immunoglobulin (Ig) 
      isotype switching and the production of IgG, a process involving presentation of 
      MHC class II binding epitopes to helper T cells (CD4+ T cells) and subsequent B 
      cell activation. DCs, CD4+ T cells and MHC class II binding epitopes are also 
      involved in self-tolerance. While many assay formats are available for reliable 
      antibody detection, the complex in vivo interplay between immunogenicity and 
      tolerance hinders accurate pre-clinical predictions of protein drug 
      immunogenicity to humans.
FAU - Barbosa, Maria D F S
AU  - Barbosa MD
AD  - CA Consultants, PO Box 3149, San Dimas, CA 91773, USA. Mbarbosa@cacobio.com
FAU - Celis, Esteban
AU  - Celis E
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20070730
PL  - England
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Animals
MH  - Antibody Formation/*immunology
MH  - Drug Design
MH  - Drug Industry/methods
MH  - Humans
MH  - Immune Tolerance/*immunology
MH  - Models, Theoretical
MH  - Recombinant Proteins/*immunology/*therapeutic use
RF  - 109
EDAT- 2007/08/21 09:00
MHDA- 2007/10/31 09:00
CRDT- 2007/08/21 09:00
PHST- 2007/08/21 09:00 [pubmed]
PHST- 2007/10/31 09:00 [medline]
PHST- 2007/08/21 09:00 [entrez]
AID - S1359-6446(07)00252-8 [pii]
AID - 10.1016/j.drudis.2007.06.005 [doi]
PST - ppublish
SO  - Drug Discov Today. 2007 Aug;12(15-16):674-81. doi: 10.1016/j.drudis.2007.06.005. 
      Epub 2007 Jul 30.